The data from these two trials suggest that response does not appear to be conditioned by the type of mutation, since response was similar among patients with somatic, germline, monoallelic, and biallelic mutations [99,101] a finding that was confirmed in the recent study by Jonsson et al. [105], who evaluated the role of BRCA1 and BRCA2 mutations in more than 17,000 patients (including 1042 with PCa). The gene discussed is BRCA1; the disease is posterior cortical atrophy.